Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.
Marina Kremyanskaya, MD, PhD, assistant professor of medicine, hematology, and medical oncology at Mount Sinai Hospital, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.
A phase II clinical trial examined the efficacy of the selective and potent oral small molecule BET inhibitor CPI-0610 as monotherapy or in combination with ruxolitinib (Jakafi) in patients with myelofibrosis, says Kremyanskaya. Arm 1 of the study examined single-agent CPI-0610 in patients no longer on ruxolitinib. In arm 2 of the study, CPI-0610 was added to ruxolitinib in patients already receiving the JAK/STAT inhibitor for at least 6 months.
In the study, investigators are looking for the typical responses patients with myelofibrosis have. Patients with this disease tend to have anemia and splenomegaly; therefore, a focus of the study was to look for improvement in splenomegaly with the treatment. Another parameter of the trial is improvement in bone marrow fibrosis as a marker of the disease process itself and then other blood counts, such as thrombocytopenia, adds Kremyanskaya.